Boston Scientific (BSX) said Friday the US Food and Drug Administration approved the Farawave NAV ablation catheter for the treatment of paroxysmal atrial fibrillation.
The FDA also issued a 510(k) clearance for the company's Faraview software that magnetically tracks the Farawave catheter. The two technologies, in combination with the company's OPAL HD mapping system, will provide visualization for cardiac ablation procedures with its Farapulse pulsed field ablation system, Boston Scientific said.
The company plans to will launch technologies immediately in the US.
Price: 89.11, Change: +1.04, Percent Change: +1.18
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。